Real-world COVID-19 Vaccine Effectiveness and the Mass Vaccination Experience in Israel

Speaker: Ben Reis, PhD, at Harvard Medical School

Date: March 16, 2021 at 2:00PM - 3:00PM

Dr. Ben Reis will lead a discussion on the recent New England Journal of Medicine paper he co-authored, providing the first real-world study of effectiveness of the Pfizer-BioNTech COVID-19 vaccine. It was the largest study yet to quantify the impact of the vaccine outside the confines of a clinical trial. The study used innovative epidemiological methods to analyze vaccine effectiveness for preventing symptomatic diseases, severe illness and death. Dr. Reis will discuss his study and the lessons learned from the nation-wide mass vaccination experience in Israel. The study has been featured in The New York TimesBloomberg, and Fortune.

Dr. Ben Reis is Director of the Predictive Medicine Group at Harvard Medical School and the Children’s Hospital Informatics Program. His research focuses on understanding the essential patterns of human disease, and on developing novel approaches for predicting disease. He has created systems that allow doctors to predict dangerous clinical conditions years in advance, as well as predictive pharmacology systems that allow public health officials to identify life-threatening adverse drug effects years in advance. Dr. Reis has designed predictive health monitoring systems for regional and national settings, and has advised governments worldwide on establishing biodefense and biosurveillance infrastructures. He has been recognized by the White House for his work on harnessing social networks to promote health, and by the US State Department, USAID and NASA for his work in global health innovation.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.